Phase 4 Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have chronic, stable heart failure with symptoms that are mild or absent (known as NYHA Class I or II), and whose fluid levels are well managed
- People whose kidneys are functioning above a certain level (confirm with trial site for exact threshold)
- People whose blood potassium level falls within a specific normal range at the time of screening
- People whose heart failure medications have been stable and are not expected to change during the 8-week study period
- People who have not had a worsening heart failure episode in the past 60 days
- People with a resting blood pressure reading above a certain level — the exact threshold differs depending on whether the person is already taking a type of medication called an MRA (confirm with trial site)
Who may not be able to join:
- People with uncontrolled high blood pressure above a certain level
- People with severe bladder problems
- People currently taking a high dose of certain fluid or potassium-related medications (confirm with trial site for specific medications and doses)
- People for whom starting or stopping the study medication spironolactone would be medically unsafe
- People with a history of severely high potassium levels in their blood
- People whose heart failure is highly sensitive to fluid changes, or who have certain specific heart conditions that would make the study treatment higher risk
- People who are pregnant or breastfeeding
- Women who are able to become pregnant and are not using a highly effective form of contraception — acceptable methods listed in the trial protocol include hormonal contraception (pill, patch, injection, implant, or vaginal ring), an intrauterine device (IUD or IUS), a surgical procedure to block the fallopian tubes, a vasectomised partner, or complete sexual abstinence — and agreement to continue contraception until at least 14 days after the last study dose is required
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jeffrey Testani, MD, Yale University
Phone: 2037857917
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
change in urine sodium to potassium ratio
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.